Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. more
Time Frame | VINC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.22% | -3.72% | -0.05% |
1-Month Return | -30.14% | -1.85% | 2.75% |
3-Month Return | -72.48% | -11.4% | 7.4% |
6-Month Return | -70.19% | -4.41% | 10.47% |
1-Year Return | -69.18% | 4.13% | 27.57% |
3-Year Return | -98.06% | 0.3% | 29.56% |
5-Year Return | -97.94% | 36.62% | 89.3% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 173.00K | 340.00K | 939.00K | 915.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":18.42,"profit":true},{"date":"2021-12-31","value":36.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.44,"profit":true}] |
Gross Profit | - | (173.00K) | (340.00K) | (939.00K) | (915.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-17299600,"profit":false},{"date":"2021-12-31","value":-34000000,"profit":false},{"date":"2022-12-31","value":-93900000,"profit":false},{"date":"2023-12-31","value":-91500000,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 45.00K | 10.71M | 62.66M | 71.11M | 42.61M | [{"date":"2019-12-31","value":0.06,"profit":true},{"date":"2020-12-31","value":15.07,"profit":true},{"date":"2021-12-31","value":88.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.92,"profit":true}] |
Operating Income | (45.00K) | (10.71M) | (62.66M) | (73.57M) | (42.61M) | [{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1071400000,"profit":false},{"date":"2021-12-31","value":-6265600000,"profit":false},{"date":"2022-12-31","value":-7357400000,"profit":false},{"date":"2023-12-31","value":-4260900000,"profit":false}] |
Total Non-Operating Income/Expense | - | (16.00K) | 23.35M | 8.87M | 3.96M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.07,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":37.99,"profit":true},{"date":"2023-12-31","value":16.98,"profit":true}] |
Pre-Tax Income | (45.00K) | (10.72M) | (39.31M) | (65.37M) | (40.16M) | [{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false}] |
Income Taxes | (54.00) | 8.00K | (23.70M) | (8.21M) | - | [{"date":"2019-12-31","value":-0.68,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-296225,"profit":false},{"date":"2022-12-31","value":-102587.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (10.73M) | (15.61M) | (57.16M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (10.72M) | (39.31M) | (65.37M) | (48.85M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4885000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (45.00K) | (10.73M) | (15.61M) | (57.16M) | (40.16M) | [{"date":"2019-12-31","value":-4500000,"profit":false},{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false}] |
EPS (Diluted) | (0.00) | (2.38) | (2.28) | (3.12) | (1.89) | [{"date":"2019-12-31","value":-0.2,"profit":false},{"date":"2020-12-31","value":-238,"profit":false},{"date":"2021-12-31","value":-228,"profit":false},{"date":"2022-12-31","value":-312,"profit":false},{"date":"2023-12-31","value":-189,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VINC | |
---|---|
Cash Ratio | 1.86 |
Current Ratio | 2.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VINC | |
---|---|
ROA (LTM) | -65.99% |
ROE (LTM) | -142.45% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VINC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.39 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.61 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VINC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.71 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Vincerx Pharma Inc (VINC) share price today is $0.1926
Yes, Indians can buy shares of Vincerx Pharma Inc (VINC) on Vested. To buy Vincerx Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VINC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vincerx Pharma Inc (VINC) via the Vested app. You can start investing in Vincerx Pharma Inc (VINC) with a minimum investment of $1.
You can invest in shares of Vincerx Pharma Inc (VINC) via Vested in three simple steps:
The 52-week high price of Vincerx Pharma Inc (VINC) is $9.37. The 52-week low price of Vincerx Pharma Inc (VINC) is $0.18.
The price-to-earnings (P/E) ratio of Vincerx Pharma Inc (VINC) is
The price-to-book (P/B) ratio of Vincerx Pharma Inc (VINC) is 0.71
The dividend yield of Vincerx Pharma Inc (VINC) is 0.00%
The market capitalization of Vincerx Pharma Inc (VINC) is $10.48M
The stock symbol (or ticker) of Vincerx Pharma Inc is VINC